Abbott has entered into a definitive agreement to acquire Kos Pharmaceuticals in a transaction valued at $3.7 billion. Kos is a specialty pharmaceutical company that develops and markets proprietary medications for the treatment of chronic cardiovascular, metabolic and respiratory diseases. Kos is based in Cranbury, NJ. “Kos Pharmaceuticals is an excellent strategic fit for Abbott, both scientifically and commercially,” said Miles D. White, chairman and chief executive officer, ...